LIONCO PHARMACEUTICAL GROUP CO.,LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.73 CNY | +2.16% |
|
+19.14% | -14.47% |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 3,604 | 3,740 | 6,150 | 7,204 | 4,140 | 3,988 |
| Enterprise Value (EV) 1 | 2,962 | 3,124 | 5,480 | 6,588 | 3,795 | 3,820 |
| P/E ratio | 19.8 x | 18.6 x | 39.2 x | 111 x | -21.3 x | -26.3 x |
| Yield | 4.55% | 5.45% | 2.32% | 1% | - | - |
| Capitalization / Revenue | 2.16 x | 2.29 x | 6.14 x | 9.73 x | 14.3 x | 20.3 x |
| EV / Revenue | 1.77 x | 1.91 x | 5.47 x | 8.9 x | 13.1 x | 19.4 x |
| EV / EBITDA | 18.6 x | 14.6 x | 39.2 x | 85.3 x | -27.1 x | -29.2 x |
| EV / FCF | -34.6 x | 26.7 x | -68.1 x | -40.3 x | -67.8 x | -107 x |
| FCF Yield | -2.89% | 3.74% | -1.47% | -2.48% | -1.48% | -0.94% |
| Price to Book | 2.62 x | 2.85 x | 4.16 x | 4.94 x | 3.65 x | 4.18 x |
| Nbr of stocks (in thousands) | 713,440 | 713,440 | 713,440 | 721,167 | 721,228 | 721,239 |
| Reference price 2 | 5.051 | 5.243 | 8.620 | 9.990 | 5.740 | 5.530 |
| Announcement Date | 4/26/19 | 4/17/20 | 4/16/21 | 4/29/22 | 4/22/23 | 4/20/24 |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 1,669 | 1,635 | 1,001 | 740.3 | 289.3 | 196.8 |
| EBITDA 1 | 158.9 | 213.3 | 139.6 | 77.2 | -140.2 | -131 |
| EBIT 1 | 129.3 | 177.9 | 102.7 | 38.59 | -177 | -170 |
| Operating Margin | 7.75% | 10.88% | 10.26% | 5.21% | -61.2% | -86.36% |
| Earnings before Tax (EBT) 1 | 204.2 | 222.9 | 179.3 | 70.48 | -188.8 | -151 |
| Net income 1 | 182.7 | 201.6 | 160.1 | 65.9 | -195.7 | -151.5 |
| Net margin | 10.94% | 12.33% | 15.99% | 8.9% | -67.67% | -76.97% |
| EPS 2 | 0.2551 | 0.2826 | 0.2200 | 0.0900 | -0.2700 | -0.2100 |
| Free Cash Flow 1 | -85.64 | 116.8 | -80.52 | -163.6 | -56 | -35.79 |
| FCF margin | -5.13% | 7.14% | -8.04% | -22.1% | -19.36% | -18.19% |
| FCF Conversion (EBITDA) | - | 54.77% | - | - | - | - |
| FCF Conversion (Net income) | - | 57.94% | - | - | - | - |
| Dividend per Share 2 | 0.2296 | 0.2857 | 0.2000 | 0.1000 | - | - |
| Announcement Date | 4/26/19 | 4/17/20 | 4/16/21 | 4/29/22 | 4/22/23 | 4/20/24 |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 641 | 617 | 670 | 617 | 345 | 168 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | -85.6 | 117 | -80.5 | -164 | -56 | -35.8 |
| ROE (net income / shareholders' equity) | 13.6% | 15% | 11.5% | 4.49% | -15.1% | -14.7% |
| ROA (Net income/ Total Assets) | 4.35% | 5.59% | 2.77% | 0.92% | -5.06% | -6.11% |
| Assets 1 | 4,205 | 3,609 | 5,775 | 7,146 | 3,865 | 2,481 |
| Book Value Per Share 2 | 1.930 | 1.840 | 2.070 | 2.020 | 1.570 | 1.320 |
| Cash Flow per Share 2 | 1.000 | 0.7200 | 2.200 | 1.370 | 0.8000 | 0.4900 |
| Capex 1 | 174 | 10.9 | 62 | 54.8 | 42.8 | 23.1 |
| Capex / Sales | 10.4% | 0.66% | 6.19% | 7.4% | 14.81% | 11.75% |
| Announcement Date | 4/26/19 | 4/17/20 | 4/16/21 | 4/29/22 | 4/22/23 | 4/20/24 |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -14.47% | 460M | |
| +20.49% | 43.67B | |
| +20.67% | 22.51B | |
| +14.04% | 14.6B | |
| +14.29% | 13.74B | |
| +44.70% | 11.91B | |
| -8.37% | 7.04B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +10.21% | 5.42B |
- Stock Market
- Equities
- 603669 Stock
- Financials Lionco Pharmaceutical Group Co.,Ltd.
